Product Description
DUET-01 consists of two functional elements: An siRNA-based inhibitor of STAT3 to release immunosuppressionn and A CpG oligonucleotide to target STAT3 inhibitor into tumor-resident myeloid cells, which then activates TLR9 to jump-start a T cell-mediated immune response for B-cell non-Hodgkin lymphoma. (Sourced from: https://duettx.com/pipeline/)
Mechanisms of Action: STAT3 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Duet Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/23/2024 |
News Article |
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting |
|
04/24/2024 |
News Article |
SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting |
|
11/10/2022 |
News Article |
SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting |
|
11/10/2022 |
News Article |
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer |